{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T20:37:14Z","timestamp":1726000634576},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1007\/s11936-002-0022-4","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T12:55:53Z","timestamp":1180875353000},"page":"429-440","source":"Crossref","is-referenced-by-count":6,"title":["Antithrombotic secondary prevention after stroke"],"prefix":"10.1007","volume":"4","author":[{"given":"Hans-Christoph","family":"Diener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ringleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"22_CR1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/01.STR.21.6.848","volume":"21","author":"M Dennis","year":"1991","unstructured":"Dennis M, Bamford J, Sandercock P, et al.: The prognosis of transient ischemic attacks in the community: the Oxfordshire Community Stroke project. Stroke 1991, 21:848\u2013853.","journal-title":"Stroke"},{"key":"22_CR2","first-page":"142","volume":"237","author":"GJ Hankey","year":"1990","unstructured":"Hankey GJ, Warlow CP, Slattery J: The prognosis of transient ischemic attacks. J Neurol 1990, 237:142.","journal-title":"J Neurol"},{"key":"22_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archneur.1992.00530320089016","volume":"49","author":"JL Wilterdink","year":"1992","unstructured":"Wilterdink JL, Easton JD: Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992, 49:857\u2013863.","journal-title":"Arch Neurol"},{"key":"22_CR4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.STR.21.2.201","volume":"21","author":"The Amaurosis Fugax Study Group","year":"1990","unstructured":"The Amaurosis Fugax Study Group: Current management of amaurosis fugax. Stroke 1990, 21:201\u2013208.","journal-title":"Stroke"},{"key":"22_CR5","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.STR.28.12.2557","volume":"28","author":"R Gueyffier","year":"1997","unstructured":"Gueyffier R, Boissel JP, Boutitie F, et al.: Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997, 28:2557\u20132562.","journal-title":"Stroke"},{"key":"22_CR6","doi-asserted-by":"crossref","unstructured":"Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Progress Collaborative Group [no authors listed]. Lancet 2001,358:1033\u20131041.","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"22_CR7","first-page":"1383","volume":"344","author":"The Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"The Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383\u20131389.","journal-title":"Lancet"},{"key":"22_CR8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.STR.28.5.946","volume":"28","author":"GJ Blauw","year":"1997","unstructured":"Blauw GJ, Lagaay AM, Smelt AHM, et al.: Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMGCoA reductase inhibitors. Stroke 1997, 28:946\u2013950.","journal-title":"Stroke"},{"key":"22_CR9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/01.CIR.99.2.216","volume":"99","author":"JF Plehn","year":"1999","unstructured":"Plehn JF, Davis BR, Sacks FM, et al.: Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999, 99:216\u2013223.","journal-title":"Circulation"},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(05)78991-1","volume":"351","author":"C Rosendorff","year":"1998","unstructured":"Rosendorff C: Statins for prevention of stroke. Lancet 1998, 351:1002\u20131003.","journal-title":"Lancet"},{"key":"22_CR11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group","year":"1998","unstructured":"The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349\u20131357.","journal-title":"N Engl J Med"},{"key":"22_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJM200008033430502","volume":"343","author":"HD White","year":"2000","unstructured":"White HD, Simes RJ, Anderson NE, et al.: Pravastatin therapy and the risk of stroke. N Engl J Med 2000, 343:317\u2013326.","journal-title":"N Engl J Med"},{"key":"22_CR13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","volume":"84","author":"J Shepherd","year":"1999","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al.: The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999, 84:1192\u20131197.","journal-title":"Am J Cardiol"},{"key":"22_CR14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410\u2013418.","journal-title":"N Engl J Med"},{"key":"22_CR15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977\u2013986.","journal-title":"N Engl J Med"},{"key":"22_CR16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bmj.296.6618.320","volume":"296","author":"Antiplatelet Trialists Collaboration","year":"1988","unstructured":"Antiplatelet Trialists Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988, 296:320\u2013331.","journal-title":"BMJ"},{"key":"22_CR17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/01.STR.27.4.756","volume":"27","author":"C Patrono","year":"1996","unstructured":"Patrono C, Roth GJ: Aspirin in ischemic cerebro-vascular disease. Stroke 1996, 27:756\u2013760.","journal-title":"Stroke"},{"key":"22_CR18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/01.STR.16.3.406","volume":"16","author":"American-Canadian Co-operative Study Group","year":"1985","unstructured":"American-Canadian Co-operative Study Group: Persantin-aspirin in cerebral ischemia, part II: endpoint results. Stroke 1985, 16:406\u2013415.","journal-title":"Stroke"},{"key":"22_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists Collaboration","year":"1994","unstructured":"Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81\u2013106.","journal-title":"BMJ"},{"key":"22_CR20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/01.STR.25.7.1337","volume":"25","author":"RG Hart","year":"1994","unstructured":"Hart RG, Halperin JL: Atrial fibrillation and stroke: revisiting the dilemmas. Stroke 1994, 25:1337\u20131341.","journal-title":"Stroke"},{"key":"22_CR21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199108153250701","volume":"325","author":"North American Symptomatic Carotid Endarterectomy Trial Collaborators","year":"1991","unstructured":"North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325:445\u2013453.","journal-title":"N Engl J Med"},{"key":"22_CR22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(97)09292-1","volume":"351","author":"European Carotid Surgery Trialists Collaborative Group","year":"1998","unstructured":"European Carotid Surgery Trialists Collaborative Group: Randomized trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998, 351:1379\u20131387.","journal-title":"Lancet"},{"key":"22_CR23","first-page":"1351","volume":"2","author":"The ESPS Group","year":"1987","unstructured":"The ESPS Group: The European Stroke Prevention Study (ESPS). Principal end-points. Lancet 1987, 2:1351\u20131354.","journal-title":"Lancet"},{"key":"22_CR24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0022-510X(97)90039-3","volume":"151","author":"HC Diener","year":"1997","unstructured":"Diener HC, Forbes C, Riekkinen PJ, et al.: European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci 1997, 151:S1-S77.","journal-title":"J Neurol Sci"},{"key":"22_CR25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","volume":"1","author":"M Gent","year":"1989","unstructured":"Gent M, Blakely JA, Easton JD, et al.: The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989, 1:1215\u20131220.","journal-title":"Lancet"},{"key":"22_CR26","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(97)22022-2","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","unstructured":"International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997, 349:1564\u20131565.","journal-title":"Lancet"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","volume":"349","author":"CAST (Chinese Acute Stroke Trial) Collaborative Group","year":"1997","unstructured":"CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997, 349:1641\u20131649.","journal-title":"Lancet"},{"key":"22_CR28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","volume":"54","author":"UK-TIA Study Group","year":"1991","unstructured":"UK-TIA Study Group: The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044\u20131054.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"22_CR29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0140-6736(91)92233-R","volume":"338","author":"The SALT Collaborative Group","year":"1991","unstructured":"The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75-mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991, 338:1345\u20131349.","journal-title":"Lancet"},{"key":"22_CR30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00867583","volume":"239","author":"ESPS-Working Group","year":"1992","unstructured":"ESPS-Working Group: Second European stroke prevention study. J Neurol 1992, 239:299\u2013301.","journal-title":"J Neurol"},{"key":"22_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1996","unstructured":"Diener HC, Cuhna L, Forbes C, et al.: European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1\u201313.","journal-title":"J Neurol Sci"},{"key":"22_CR32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","volume":"321","author":"WK Hass","year":"1989","unstructured":"Hass WK, Easton JD, Adams HP, et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. N Engl J Med 1989, 321:501\u2013507.","journal-title":"N Engl J Med"},{"key":"22_CR33","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348:1329\u20131339.","journal-title":"Lancet"},{"key":"22_CR34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/01.STR.23.10.1395","volume":"23","author":"ML Dyken","year":"1992","unstructured":"Dyken ML, Barnett HJM, Easton JD, et al.: Low-dose aspirin and stroke: \u201c It ain\u2019t necessarily so\u201d. Stroke 1992, 23:1395\u20131399.","journal-title":"Stroke"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1161\/01.STR.24.8.1251","volume":"24","author":"ML Dyken","year":"1993","unstructured":"Dyken ML: Controversies in stroke: past and present. The Willis lecture. Stroke 1993, 24:1251\u20131258.","journal-title":"Stroke"},{"key":"22_CR36","doi-asserted-by":"crossref","unstructured":"Diener HC: Use of acetylsalicylic acid in the secondary prevention of stroke. Int J Clin Pract 1998, Suppl 97:12\u201315.","DOI":"10.1111\/j.1742-1241.1998.tb11573.x"},{"key":"22_CR37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.60.2.197","volume":"60","author":"A Algra","year":"1996","unstructured":"Algra A, van GijnJ: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry 1996, 60:197\u2013199.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"22_CR38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jnnp.66.2.255","volume":"65","author":"A Algra","year":"1999","unstructured":"Algra A, van Gijn J: Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. J Neurol Neurosurg Psychiatry 1999, 65:255. A good review.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"22_CR39","first-page":"56802","volume":"63","author":"Department of Health and Human Services, US Food and Drug Administration","year":"1998","unstructured":"Department of Health and Human Services, US Food and Drug Administration: Internal analgesic, antipyretic, and anti-rheumatic drug products for overthe counter human use. Final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register 1998, 63:56802\u201356819.","journal-title":"Federal Register"},{"key":"22_CR40","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","volume":"325","author":"The Dutch TIA Trial Study Group","year":"1991","unstructured":"The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg\/day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261\u20131266.","journal-title":"N Engl J Med"},{"key":"22_CR41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/0140-6736(91)91383-6","volume":"337","author":"Y Page","year":"1991","unstructured":"Page Y, Tardy B, Zeni F, et al.: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991, 337:774\u2013776.","journal-title":"Lancet"},{"key":"22_CR42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(05)60079-7","volume":"352","author":"CL Bennett","year":"1998","unstructured":"Bennett CL, Kiss JE, Weinberg PD, et al.: Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998, 352:1036\u20131037.","journal-title":"Lancet"},{"key":"22_CR43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","volume":"342","author":"CL Bennett","year":"2000","unstructured":"Bennett CL, Connors JM, Carwile JM, et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:1773\u20131777. An excellent article.","journal-title":"N Engl J Med"},{"key":"22_CR44","doi-asserted-by":"crossref","first-page":"470S","DOI":"10.1378\/chest.114.5_Supplement.470S","volume":"114","author":"C Patrono","year":"1998","unstructured":"Patrono C, Coller B, Dalen JE, et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998, 114(suppl):470S-488S.","journal-title":"Chest"},{"key":"22_CR45","first-page":"367","volume":"138","author":"B Guiraud-Chaumeil","year":"1982","unstructured":"Guiraud-Chaumeil B, Rascol A, David J, et al.: Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires. Rev Neurol (Paris) 1982, 138:367\u2013385.","journal-title":"Rev Neurol (Paris)"},{"key":"22_CR46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","volume":"13","author":"MG Bousser","year":"1983","unstructured":"Bousser MG, Eschwege E, Haguenau M, et al.: \" A.I.C.L.A.\" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983, 13:5\u201314.","journal-title":"Stroke"},{"key":"22_CR47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.1990.tb03763.x","volume":"30","author":"TH M\u00fcller","year":"1990","unstructured":"M\u00fcller TH, Su CA, Weisenberger H, et al.: Dipyridamole alone or combined with low dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990, 30:179\u2013186.","journal-title":"Br J Clin Pharmacol"},{"key":"22_CR48","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","volume":"342","author":"EAFT Group","year":"1993","unstructured":"EAFT Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255\u20131262.","journal-title":"Lancet"},{"key":"22_CR49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","volume":"42","author":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","unstructured":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997, 42:857\u2013865.","journal-title":"Ann Neurol"},{"key":"22_CR50","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","volume":"345","author":"JP Mohr","year":"2001","unstructured":"Mohr JP, Thompson JL, Lazar RM, et al.: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444\u20131451.","journal-title":"N Engl J Med"},{"key":"22_CR51","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.45.8.1488","volume":"45","author":"M Chimowitz","year":"1995","unstructured":"Chimowitz M, Kokkinos J, Strong J, et al.: The warfarin-aspirin symptomatic intracranial disease study. Neurology 1995, 45:1488\u20131493.","journal-title":"Neurology"},{"key":"22_CR52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","volume":"353","author":"EJ Topol","year":"1999","unstructured":"Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers. Lancet 1999, 353:227\u2013231.","journal-title":"Lancet"},{"key":"22_CR53","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1067\/mhj.2000.105107","volume":"139","author":"EJ Topol","year":"2000","unstructured":"Topol EJ, Eston JD, Amarenco P, et al.: Design of the blockade of the glycoprotein IIb\/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J 2000, 139:927\u2013933.","journal-title":"Am Heart J"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-002-0022-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-002-0022-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-002-0022-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:37:02Z","timestamp":1683866222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-002-0022-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s11936-002-0022-4","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}